Article
Immunology
Changju Qu, Rui Zou, Peng Wang, Qian Zhu, Liqing Kang, Nana Ping, Fan Xia, Hailing Liu, Danqing Kong, Lei Yu, Depei Wu, Zhengming Jin
Summary: This study demonstrates that CD19/CD22 dual-targeted CAR-T therapy, under a decitabine-containing lymphodepletion regimen, may be a safe and potent effective approach for patients with relapsed/refractory DLBCL.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Chiara Monfrini, Federico Stella, Vanessa Aragona, Martina Magni, Silva Ljevar, Cristina Vella, Eugenio Fardella, Annalisa Chiappella, Francesca Nanetti, Martina Pennisi, Anna Dodero, Anna Guidetti, Paolo Corradini, Cristiana Carniti
Summary: This study found that the in vivo expansion of CAR T cells is associated with therapeutic efficacy. Additionally, the content and characteristics of CAR T bag cells have a significant impact on in vivo expansion, treatment response, and survival.
CLINICAL CANCER RESEARCH
(2022)
Review
Immunology
Massimiliano Gambella, Simona Carlomagno, Anna Maria Raiola, Livia Giannoni, Chiara Ghiggi, Chiara Setti, Chiara Giordano, Silvia Luchetti, Alberto Serio, Alessandra Bo, Michela Falco, Mariella Della Chiesa, Emanuele Angelucci, Simona Sivori
Summary: Surgical resection, chemotherapy, and radiotherapy have been the primary cancer treatments for a long time. Recently, immune checkpoint inhibitors and adoptive cell therapies have emerged as promising alternatives. These therapies aim to activate and utilize the patient's immune system to fight against cancer cells, and have shown remarkable results.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Qingzhu Jia, Diyuan Qin, Feng He, Qichao Xie, Zhitao Ying, Yajing Zhang, Yuqin Song, Jia-Nan Cheng, Xuejiao Zuo, Luxiang Xu, Hongliang Fang, Chunyan Hu, Lina Peng, Tao Jin, Zixiao Shi, Peter B. Alexander, Yongsheng Wang, Yarong Liu, Weidong Han, Jun Zhu, Pin Wang, Qi-Jing Li, Bo Zhu
Summary: This study identified the baseline high eosinophil count as a potential biomarker for predicting the clinical efficacy of CAR-T cell therapy in B-NHL patients. A preclinical model demonstrated that depletion of eosinophils could impair the intratumoral infiltration and antitumor efficacy of CAR-T cells.
Article
Multidisciplinary Sciences
Christine Ambrose, Lihe Su, Lan Wu, Fay J. Dufort, Thomas Sanford, Alyssa Birt, Benjamin J. Hackel, Andreas Hombach, Hinrich Abken, Roy R. Lobb, Paul D. Rennert
Summary: Successful CAR T cell therapy for solid tumors requires exemplary expansion, persistence, fitness, and safe targeting of tumor antigens. A developed CAR-CD19 T cell, secreting a CD19-anti-Her2 bridging protein, shows potential for successful solid tumor cell therapy through efficient cytotoxicity targeting multiple different tumor antigens.
Article
Hematology
John H. Baird, Matthew J. Frank, Juliana Craig, Shabnum Patel, Jay Y. Spiegel, Bita Sahaf, Jean S. Oak, Sheren F. Younes, Michael G. Ozawa, Eric Yang, Yasodha Natkunam, John Tamaresis, Zachary Ehlinger, Warren D. Reynolds, Sally Arai, Laura Johnston, Robert Lowsky, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Surbhi Sidana, Wen-Kai Weng, Kara L. Davis, Sneha Ramakrishna, Liora Schultz, Chelsea Mullins, Allison Jacob, Ilan Kirsch, Steven A. Feldman, Crystal L. Mackall, David B. Miklos, Lori Muffly
Summary: Despite poor prognosis in LBCL patients following CAR19 therapy failure, treatment with CAR22 in three consecutive patients showed promising results with all patients achieving complete remission and experiencing tolerable side effects, suggesting potential efficacy of CAR22 therapy in this population.
Article
Hematology
Tanya Siddiqi, Xiuli Wang, M. Suzette Blanchard, Jamie R. Wagner, Leslie L. Popplewell, L. Elizabeth Budde, Tracey L. Stiller, Mary C. Clark, Laura Lim, Vibhuti Vyas, Christine E. Brown, Stephen J. Forman
Summary: The CD19CAR T-cell therapy shows promise in treating primary CNS lymphoma, with manageable toxicity and potential for disease remission. Despite mild toxicities observed in patients, the treatment is reversible and well-tolerated, leading to significant improvement in most cases.
Article
Immunology
Weiguo Zhu, Shi Tao, Wenchun Miao, Hui Liu, Xianggui Yuan
Summary: We report the first successful case of dual inhibition of HDAC and BTK for the treatment of R/R DLBCL after failure to CAR-T cell therapy, which opens a new therapeutic possibility for the future.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jiachen Wang, Kefeng Shen, Wei Mu, Weigang Li, Meilan Zhang, Wei Zhang, Zhe Li, Tong Ge, Zhoujie Zhu, Shangkun Zhang, Caixia Chen, Shugang Xing, Li Zhu, Liting Chen, Na Wang, Liang Huang, Dengju Li, Min Xiao, Jianfeng Zhou
Summary: This study retrospectively evaluated the treatment outcomes of murine CD19/CD22 cocktail CAR T-cell therapy in 135 DLBCL patients. The study found that higher levels of lactate dehydrogenase before leukapheresis and lower cytokine release syndrome grade after CAR T-cell infusion were independent risk factors for T-cell dysfunction. Additionally, a variety of germline variants in genes related to T-cell immunity were significantly enriched in the group with T-cell defects.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Lihe Su, Lan Wu, Roy R. Lobb, Paul D. Rennert, Christine Ambrose
Summary: CD19-targeting cellular therapeutics have shown high clinical response rates in B cell lymphoma therapy, however, many patients relapse within 6 months. Researchers have designed a novel CAR T Engager that can prevent and reverse relapses caused by loss or reduction of CD19 expression. In vitro and in vivo studies have demonstrated its effectiveness in preventing lymphoma relapse.
Review
Oncology
Austin D. Newsam, Caroline A. Coughlin, Asaad Trabolsi, Jonathan H. Schatz
Summary: CAR-19 therapy has shown impressive durable remissions for relapsed or refractory large B-cell lymphoma patients, but a significant proportion of patients still fail to respond or progress. Current research has focused on host clinical parameters, CAR-19 product composition, and tumor microenvironment alterations, with limited studies on genomic alterations in tumor cells.
LEUKEMIA & LYMPHOMA
(2023)
Article
Medicine, Research & Experimental
Jessica J. Jalbert, Ning Wu, Chieh- Chen, Srikanth Ambati, Wenzhen Ge, Jon E. Arnason
Summary: This study explores the real-world treatment patterns after CAR T in adults with DLBCL. It highlights the considerable risk of not achieving a durable response among patients treated with CAR T and the need for additional effective salvage treatment options for DLBCL.
ADVANCES IN THERAPY
(2022)
Article
Hematology
Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Fabien Le Bras, Francois-Xavier Gros, Sylvain Choquet, Pierre Bories, Pierre Feugier, Olivier Casasnovas, Jacques Olivier Bay, Mohamad Mohty, Magalie Joris, Thomas Gastinne, Pierre Sesques, Jean-Jacques Tudesq, Laetitia Vercellino, Franck Morschhauser, Elodie Gat, Florence Broussais, Roch Houot, Catherine Thieblemont
Summary: Anti-CD19 CAR T-cell therapy is a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas, but a significant number of patients experience treatment failure. Patients who fail after CAR T-cell treatment have a poor prognosis, highlighting the need for further therapeutic strategies.
Article
Oncology
Zhen Jin, Rufang Xiang, Kai Qing, Dan Li, Zhao Liu, Xiaoyang Li, Hongming Zhu, Yunxiang Zhang, Lining Wang, Kai Xue, Han Liu, Zizhen Xu, Yingxiao Wang, Junmin Li
Summary: This study demonstrates that lenalidomide can enhance the function of CD19-CAR-T cells, providing a basis for clinical trials of this combination therapy against DLBCL.
Article
Medicine, Research & Experimental
Wenjie Li, Lixia Ding, Wenhua Shi, Xinyu Wan, Xiaomin Yang, Jing Yang, Tianyi Wang, Lili Song, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang, Benshang Li
Summary: Co-administration of CD19- and CD22-targeted CAR-T cells is a safe and effective therapy for relapsed B-ALL patients, providing an opportunity for long-term survival and bridging to transplantation.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)